Straits Times Index
3,336.59 +13.21 (+0.40%) Nikkei
38,487.90 +433.77 (+1.14%) Hang Seng
18,079.61 -150.58 (-0.83%) FTSE 100
8,275.38 +44.33 (+0.54%) Bitcoin USD
67,652.38 +331.92 (+0.49%) CMC Crypto 200
1,424.49 -4.08 (-0.29%)
IOVA Dec 2024 12.000 call
| Previous close | 1.4000 |
| Open | 1.4000 |
| Bid | 1.3000 |
| Ask | 1.8000 |
| Strike | 12.00 |
| Expiry date | 2024-12-20 |
| Day's range | 1.4000 - 1.4000 |
| Contract range | N/A |
| Volume | |
| Open interest | 132 |
Simply Wall St.Exploring Three US Growth Companies With Substantial Insider Ownership
Amidst a backdrop of fluctuating markets and evolving economic indicators, the U.S. stock market has shown resilience in various sectors despite recent downturns in tech giants. As investors navigate through these uncertain times, understanding the role of insider ownership in growth companies becomes increasingly relevant. In this environment, companies with substantial insider ownership can be appealing as they often indicate a leadership team deeply invested in the company's long-term...
GlobeNewswireIovance Biotherapeutics to Present at Upcoming Conferences and Events
SAN CARLOS, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences and events: TD Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO & EHAFireside Chat: May 28, 2024 at 3:00 p.m. ETVirtual Iovance ASCO Invest
ZacksIovance (IOVA) Up 5% on Updated Data From Melanoma Study
Iovance (IOVA) shares updated data from a mid-stage study, which showed that treatment with its combination therapy achieved an objective response rate of 65% in frontline advanced melanoma.
